| scholarly article | Q13442814 |
| P356 | DOI | 10.1006/BBRC.1994.2872 |
| P698 | PubMed publication ID | 7811262 |
| P2093 | author name string | Ball MJ | |
| Cotter RJ | |||
| Woods AS | |||
| Fridman R | |||
| Roher AE | |||
| Kasunic TC | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | proteolysis | Q33123 |
| P304 | page(s) | 1755-1761 | |
| P577 | publication date | 1994-12-01 | |
| P1433 | published in | Biochemical and Biophysical Research Communications | Q864228 |
| P1476 | title | Proteolysis of A beta peptide from Alzheimer disease brain by gelatinase A. | |
| P478 | volume | 205 |
| Q39437881 | Amyloid beta: structure, biology and structure-based therapeutic development |
| Q36764094 | Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer's disease |
| Q37961852 | Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer's disease? |
| Q37755129 | Aspects of beta-amyloid as a biomarker for Alzheimer's disease |
| Q41873573 | Aβ degradation-the inside story |
| Q46335422 | Aβ truncated species: Implications for brain clearance mechanisms and amyloid plaque deposition |
| Q34750587 | Biogenesis and metabolism of Alzheimer's disease Abeta amyloid peptides |
| Q39135845 | Clearance of cerebral Aβ in Alzheimer's disease: reassessing the role of microglia and monocytes. |
| Q48812317 | Degradation of Alzheimer's beta-amyloid protein by human and rat brain peptidases: involvement of insulin-degrading enzyme |
| Q37431176 | Degradation of amyloid beta protein by purified myelin basic protein |
| Q53234549 | Degradation of soluble amyloid beta-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains. |
| Q33643056 | Degradation of soluble and fibrillar amyloid beta-protein by matrix metalloproteinase (MT1-MMP) in vitro |
| Q42723254 | Differential modulation of Alzheimer's disease amyloid beta-peptide accumulation by diverse classes of metal ligands. |
| Q34202064 | Differential spatio-temporal regulation of MMPs in the 5xFAD mouse model of Alzheimer's disease: evidence for a pro-amyloidogenic role of MT1-MMP. |
| Q42166961 | Effects of oxidative stress on amyloid precursor protein processing in rat and human platelets |
| Q90680150 | Emerging Alternative Proteinases in APP Metabolism and Alzheimer's Disease Pathogenesis: A Focus on MT1-MMP and MT5-MMP |
| Q26779933 | Friends or Foes: Matrix Metalloproteinases and Their Multifaceted Roles in Neurodegenerative Diseases |
| Q33605481 | Increased matrix metalloproteinase 9 activity in mild cognitive impairment |
| Q78609599 | Induction of matrix metalloproteinase-9 (MMP-9) in lipopolysaccharide-stimulated primary astrocytes is mediated by extracellular signal-regulated protein kinase 1/2 (Erk1/2) |
| Q74244366 | Inflammatory genes are upregulated in expanded ataxin-3-expressing cell lines and spinocerebellar ataxia type 3 brains |
| Q58124889 | Inhibition of α2-macroglobulin/proteinase-mediated degradation of amyloid β peptide by apolipoprotein E and α1-antichymotrypsin; Evidence that the α2-macroglobulin/proteinase complex mediates degradation of the Aβ peptide |
| Q53290104 | MMP-2, -3 and -9 levels and activity are not related to Abeta load in the frontal cortex in Alzheimer's disease. |
| Q49122434 | MMP-2/MMP-9 plasma level and brain expression in cerebral amyloid angiopathy-associated hemorrhagic stroke. |
| Q47856616 | MMP-7 cleaves amyloid β fragment peptides and copper ion inhibits the degradation |
| Q48700290 | Macrophage-mediated degradation of beta-amyloid via an apolipoprotein E isoform-dependent mechanism. |
| Q34094501 | Matrix metalloproteinase 2 (MMP-2) degrades soluble vasculotropic amyloid-beta E22Q and L34V mutants, delaying their toxicity for human brain microvascular endothelial cells |
| Q37486259 | Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. |
| Q48829616 | Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1-40). |
| Q36579614 | Matrix metalloproteinase-9 reduces islet amyloid formation by degrading islet amyloid polypeptide |
| Q41719486 | Matrix metalloproteinases and diseases of the CNS. |
| Q47587456 | Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-beta peptide catabolism. |
| Q48159922 | Matrix metalloproteinases in peripheral blood and cerebrospinal fluid in patients with Alzheimer's disease |
| Q38151704 | Matrix metalloproteinases, new insights into the understanding of neurodegenerative disorders |
| Q34417187 | Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview |
| Q41898767 | Matrix metalloproteinases-2 and -3 are reduced in cerebrospinal fluid with low beta-amyloid1-42 levels |
| Q34503909 | Metalloendopeptidase EC 3.4.24.15 is necessary for Alzheimer's amyloid-beta peptide degradation |
| Q33608218 | Mitochondrial DNA damage in a mouse model of Alzheimer's disease decreases amyloid beta plaque formation |
| Q33854483 | Multifaceted Roles of Metzincins in CNS Physiology and Pathology: From Synaptic Plasticity and Cognition to Neurodegenerative Disorders |
| Q48957718 | Multiple cellular and molecular mechanisms are involved in human Aβ clearance by transplanted adult astrocytes |
| Q33952436 | Multiple insulin degrading enzyme variants alter in vitro reporter gene expression |
| Q35032465 | Myocardial matrix metalloproteinase-2: inside out and upside down. |
| Q28505860 | Neprilysin degrades both amyloid beta peptides 1-40 and 1-42 most rapidly and efficiently among thiorphan- and phosphoramidon-sensitive endopeptidases |
| Q36735832 | Nitric oxide-mediated regulation of β-amyloid clearance via alterations of MMP-9/TIMP-1 |
| Q39262427 | Oleuropein, an anti-oxidant polyphenol constituent of olive promotes α-secretase cleavage of the amyloid precursor protein (AβPP). |
| Q39440830 | Organotypic vibrosections from whole brain adult Alzheimer mice (overexpressing amyloid-precursor-protein with the Swedish-Dutch-Iowa mutations) as a model to study clearance of beta-amyloid plaques |
| Q37295067 | Pharmacotherapeutic targets in Alzheimer's disease |
| Q34476355 | Physicochemical characteristics of soluble oligomeric Abeta and their pathologic role in Alzheimer's disease. |
| Q90264143 | Risk Factors for Alzheimer's Disease: Focus on Stress |
| Q46845387 | Selective intracellular release of copper and zinc ions from bis(thiosemicarbazonato) complexes reduces levels of Alzheimer disease amyloid-beta peptide |
| Q35610552 | Sequential Amyloid-β Degradation by the Matrix Metalloproteases MMP-2 and MMP-9. |
| Q37157835 | Targeted proteomics in Alzheimer's disease: focus on amyloid-beta |
| Q34493230 | The absence of myelin basic protein promotes neuroinflammation and reduces amyloid β-protein accumulation in Tg-5xFAD mice |
| Q35039021 | The degradation of amyloid beta as a therapeutic strategy in Alzheimer's disease and cerebrovascular amyloidoses |
| Q37083267 | The role of metals in modulating metalloprotease activity in the AD brain. |
| Q38136195 | The role of microglia and matrix metalloproteinases involvement in neuroinflammation and gliomas |
| Q21202832 | Transthyretin and the brain re-visited: is neuronal synthesis of transthyretin protective in Alzheimer's disease? |
| Q89052844 | Unveiling Brain Aβ Heterogeneity Through Targeted Proteomic Analysis |
| Q47683319 | Zinc and Alzheimer's Disease: An Update. |
| Q73369561 | Zinc and Alzheimer's disease: is there a direct link? |
| Q44410537 | β-Amyloid induces the production of active, matrix-degrading proteases in cultured rat astrocytes |
Search more.